Regeneron Pharmaceuticals (REGN) Insider J Sells $3.2M of Stock

Regeneron Pharmaceuticals, Inc. Co-Chief Scientific Officer Murphy Andrew J sold 4,147 shares on October 14, 2026, at a price of $772.70 each, totaling approximately $3.2 million. This sale was part of a planned transaction.

Inside Murphy Andrew J's Trade

Murphy Andrew J's sale of 4,147 shares reduced his holdings. The transaction was valued at about $3.2 million. The shares were sold under a Rule 10b5-1 plan, which allows executives to sell stock according to a predetermined schedule.

Other Institutional Activity in Regeneron Pharmaceuticals

Several institutional investors have been active with Regeneron shares. Blackrock Inc. increased its stake by 165,537 shares, bringing its total to 9,113,506 shares worth approximately $7.2 billion. Dodge & Cox Inc. also added 412,838 shares, now holding 4,871,137 shares valued at about $3.9 billion. State Street Corporation raised its holdings by 170,252 shares, ending with 4,834,688 shares worth around $3.8 billion.

Regeneron Pharmaceuticals, Inc. Stock Holds Steady

As of October 16, 2026, Regeneron shares were recently trading at $796.21, which is above both its 50-day and 200-day moving averages by 0.7% and 8.3%, respectively. However, the stock remains about 7.3% below its 52-week high of $859.34 and 40.6% above its 52-week low of $566.11. The current price is also 7.8% below the mean price target of $863.93 set by analysts.

Recent Earnings

In its most recent earnings report, Regeneron posted trailing twelve-month revenue of approximately $15.5 billion, with an EPS of $40.44. The company has shown a year-over-year revenue growth of 16.7% and a net margin of 27.9%. Regeneron is scheduled to report its next earnings on October 30, 2026.

Dividend

Regeneron Pharmaceuticals pays an annual dividend of $3.76 per share, yielding about 0.47%. The payout ratio stands at 9.0%, indicating a sustainable dividend policy.

Insider Buying and Selling at Regeneron Pharmaceuticals, Inc.

Before Murphy Andrew J's recent sale, several insiders made trades in Regeneron. Huda Y Zoghbi, a Director, sold 800 shares at $800.00 each on August 10, 2026, totaling $640,000. Kathryn Ph.D. Guarini also sold 400 shares at $800.00 on the same day, valued at $320,000, and another 400 shares at $850.00 on September 2, 2026, worth $340,000. Marion E Mccourt, an Officer, sold 2,346 shares on September 3, 2026, valued at approximately $2 million.

Analysts Set New Price Targets

Analysts have maintained their positive outlook on Regeneron. On October 1, 2026, Jefferies maintained a 'Buy' rating with a target price of $930.00, while JP Morgan set a target of $950.00 on October 6, 2026. Truist Securities and Morgan Stanley also maintained their ratings with targets of $780.00 and $779.00, respectively. The consensus recommendation remains a 'buy' with a mean target price of $863.93 from 27 analyst opinions.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company based in Tarrytown, NY. It focuses on discovering, developing, and commercializing medicines for various diseases, including eye conditions, cardiovascular diseases, and cancer. The recent insider sale may reflect strategic financial planning amid a dynamic market environment.

Bottom Line

Investors will want to monitor Regeneron's upcoming earnings report on October 30, 2026, for insights into the company's performance and outlook. Additionally, keep an eye on further insider trades and institutional activity as they can influence market sentiment.